TNXP (MC $32M) (Cash $34M) O/S 7.5 M / Phase 3 Data in 1H 2018 =More than just cheap . Found another terrible undervalued which trading below Cash and which is close to phase 3 readout if successfull the drug will have around $600+ M Market Potential . The Company has only 7.5 Million Shares outstanding and Baker bros who are really one of the most successful investors in the Biotech Sector is second largest staekholder . TNXP should be valued right now around $15 per share for their Phase 3 program and huge cash balance and if phase 3 outcome is positive then sky is the limit .GL Tonix Pharma (TNXP) Market Cap: $32 Million Cash: $34.5 Million Kurs: $4.25 Shares Out: 7.5 Million New Presentation http://content.equisolve.net/tonixpharma/media/5834b932b328c4417b28ea179cb3f7c8.pdf Phase 3 HONOR study of Tonmya in military-related PTSD enrolling •Encouraging evidence of safety and efficacy was demonstrated in Phase 2 Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) •Expedited development and accelerated review are expected •Potential to file NDA based on one Phase 3 study if data are statistically persuasive Proposed registration plan agreed by the FDA •Additional nonclinical safety and clinical abuse potential studies are not required Patent protection through 2034 in U.S. •Composition of matter patent for eutectic, required for transmucosal delivery of cyclobenzaprine TNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18 https://finance.yahoo.com/news/tnxp-patient-enrollment-continues-phase-161500725.html Conclusion and Valuation The U.S. military’s intense interest in identifying safe and effective PTSD treatments is important for Tonix, as the AtEase study is the only controlled clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated in the HONOR study (and Tonmya® gets approved), the Department of Defense and the VA would likely be very interested in getting the treatment to military personnel and veterans who suffer from PTSD. Our valuation for Tonix is derived from a probability adjusted discounted cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximately 8.6 million individuals in the U.S. who suffer from PTSD, it’s estimated that approximately 20% seek treatment. With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probability of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable fully diluted share count of 8.1 million shares leads to a valuation of approximately $13 per share. Insider & Institutional Ownership : Rosalind Advisors, Inc. 553 908 Baker Bros. Advisors LP 510 922 B. Riley Capital Management LLC 378 138 Opaleye Management, Inc. 370 000 Empery Asset Management LP 315 000 The Vanguard Group, Inc. 184 377 Heights Capital Management, Inc. 89 713 Seth Lederman, MD 83 400 Ernest Mario, PhD 69 718 Kingdon Capital Management LLC 64 549
trading below cash of $34 million + only 7.5 million shares outstanding + attractive product in phase 3 with results expected in 1H 2018 = The definition of a dirt cheap stock .GL
IF P3 is successful then this stock could hit $80-100 per share (= Mcap $600-750M) thats not much for a Drug with $650 million potential.GL Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better ..Sep.27.17 https://seekingalpha.com/article/4109815-tonixs-tonmya-treats-ptsd-helping-sufferers-sleep-better Summary PTSD is a serious illness that has devastating symptoms. It affects 3.5% of American adults, or 8.6m individuals each year. The prevalence of PTSD is even higher among veterans. The only FDA approved PTSD drug treatment, the SSRIs (selective serotonin reuptake inhibitors), failed to show efficacy in military-related PTSD and have serious side effects. Tonix's Tonmya is being studied in HONOR, a phase 3 trial for treating military-related PTSD. Tonmya works by improving sleep quality and allowing the mind to heal itself. This article focuses on PTSD and discusses how Tonmya can meet a very important unmet medical need.
Some resistance around $4.50 once we break it then i think stock will hit $5++ quickly http://stockcharts.com/c-sc/sc?s=tnxp&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658
Another green day maybe it will hit $5 today trading below cash , very low market cap of only $33 million , only 7.5 million shares outstanding , Baker bros one of the most successful investors in sector ups their stake , attractive product in advanced phase 3 trial with results in 1H 2018 , $650 million sales potential = A MEGA OPPORTUNITY HERE it will move up faster the closer we get to the phase3 results .
If you guys want that the stock moving even faster then put your shares on high GTC sell order like $10 this helps to prevent your shares from being shorted and more important your shares wouldnt be available on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news. This works good especially on stocks like TNXP which has ony 7.5 million shares outstanding .Thank you How to Prevent your Shares Holdings from being Shorted http://www.contracts-for-difference.com/Borrowing-lending-shares.html
Another good day but real jump will start once we hit the $5 mark because many Institutions who are not allowed to buy stock under $5 will start jump in . Stock is still a gift here trading at Cash and with a advanced Phase 3 program close to readout .GL
